Clinical Trial Update: A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study PF-00610355 in chronic obstructive pulmonary disease has completed, evaluating safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PF-00610355

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases | Phase 2 | Status: COMPLETED